With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...
For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.
Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...
Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...
Weight loss drugs like Ozempic and Wegovy have dominated the diet discussion for the past few years. But this trend leaves many people wondering: What role does weight-loss surgery play in an ...
The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback